Sanofi (Sanofi) Long-Term Debt : $15,429 Mil (As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi Long-Term Debt?

Sanofi's Long-Term Debt for the quarter that ended in Jun. 2023 was $15,429 Mil.

Sanofi's quarterly Long-Term Debt declined from Jun. 2022 ($16,852 Mil) to Dec. 2022 ($15,738 Mil) and declined from Dec. 2022 ($15,738 Mil) to Jun. 2023 ($15,429 Mil).

Sanofi's annual Long-Term Debt declined from Dec. 2021 ($19,348 Mil) to Dec. 2022 ($15,738 Mil) and declined from Dec. 2022 ($15,738 Mil) to Dec. 2023 ($15,646 Mil).

Sanofi Long-Term Debt Historical Data

The historical data trend for Sanofi's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Long-Term Debt Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

22,367.78

20,830.90

19,348.02

15,738.35

15,645.58

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															19,348.02	16,852.01	15,738.35	15,429.04	15,645.58

Sanofi (NAS:SNY) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sanofi Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Sanofi's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.